Electrochemotherapy for the treatment of ocular basal cell carcinoma; a novel adjunct in the disease management

J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):403-6. doi: 10.1016/j.bjps.2013.07.019. Epub 2013 Aug 1.

Abstract

Basal Cell Carcinoma (BCC) affecting the ocular region is potentially problematic due to its ability to infiltrate aesthetic and functional structures. Due to the paucity of local tissue, resection frequently requires reconstruction with skin grafts or local flaps. Surgical treatment may not be suitable for patients with multiple co-morbidities. Electrochemotherapy (ECT) is a technique where cells are temporarily permeabilized after exposure to a brief electrical field and when combined with normally impermeant chemotherapy drugs can resolve cutaneous cancers - even those previously recalcitrant to chemotherapy or radiotherapy. Its particular advantage is its speed of application and the minimal damage to the surrounding healthy tissue structures. We present a series of 3 patients with BCCs in the peri-ocular region and significant co-morbidities deemed unsuitable for surgical resection, who underwent ECT. The lesions were all primary BCC ranging in size from 0.5 cm(2) to 1 cm(2). Two lesions were on the upper eyelid and one on the lower eyelid. ECT was performed using an 8-needle electrode and a CE approved electroporation generator with intra-lesional Bleomycin. All lesions responded to treatment. All BCC's completely resolved, with acceptable scarring. No side effects were reported from the Bleomycin or the electric pulses. ECT for peri-ocular BCC is an adjunct to surgical excision in the management of surgically problematic lesions. This technique could provide a useful initial treatment option for patients who are medically unfit or where resection and would be associated with significant morbidity.

Keywords: Basal cell carcinoma; Co-morbidity; Electrochemotherapy; Ocular.

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage*
  • Bleomycin / administration & dosage*
  • Carcinoma, Basal Cell / drug therapy*
  • Electrochemotherapy
  • Eyelid Neoplasms / drug therapy*
  • Female
  • Humans
  • Injections, Intralesional
  • Skin Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Bleomycin